Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging–detected Prostate Imaging Reporting and Data System/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score
- Falagario U.G.
- Reddy D.
- Picker W.
- Cucchiara V.
- Stabile A.
- Eldred-Evans D.
- Bass E.
- Gordon S.
- Ahmed H.U.
- Taimen P.
- van Rossum P.S.N.
- Verhoeff J.J.C.
- Martini A.
- Montoya Perez I.
- Boström P.J.
- Nordström T.
- Wong K.
- Aronen H.J.
- Knaapila J.
- Lantz A.
- Connor M.J.
- Peters M.
- Qazi H.
- Kurver P.
- Gandaglia G.
- Briganti A.
- Shah T.T.
- Winkler M.
- Tam H.
- Jambor I.
- Ettala O.
- Haug E.S.
- Fossati N.
- Tanaka M.B.
Publication date
October 2022
DOI Publisher
Elsevier BV Journal
European UrologyAbstract
Background: Although multiparametric magnetic resonance imaging (MRI) has highsensitivity, its lower specificity leads to a high prevalence of false-positive lesions requir-ing biopsy.Objective: To develop and externally validate a scoring system for MRI-detected ProstateImaging Reporting and Data System (PIRADS)/Likert 3 lesions containing clinically sig-nificant prostate cancer (csPCa).Design, setting, and participants: The multicentre Rapid Access to Prostate Imaging andDiagnosis (RAPID) pathway included 1189 patients referred to urology due to elevatedage-specific prostate-specific antigen (PSA) and/or abnormal digital rectal examination (DRE); April 27, 2017 to October 25, 2019.</p
Add to ORKG